Healios K.K. (TYO:4593)

Japan · Delayed Price · Currency is JPY

247.00

-6.00 (-2.37%)

Aug 6, 2026, 10:42 AM JST

-60.29% (1Y)

Market Cap	34.16B -45.9%
Revenue (ttm)	74.00M -87.4%
Net Income	-3.13B
EPS	-34.73
Shares Out	135.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	426,100
Open	250.00
Previous Close	253.00
Day's Range	246.00 - 253.00
52-Week Range	208.00 - 654.00
Beta	1.39
Analysts	Buy
Price Target	779.83 (+215.72%)
Earnings Date	Aug 12, 2026

About Healios K.K.

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for t... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2011

Employees 75

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4593

Full Company Profile

Financial Performance

In 2025, Healios K.K.'s revenue was 104.00 million, a decrease of -81.43% compared to the previous year's 560.00 million. Losses were -2.22 billion, -47.65% less than in 2024.

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for 4593 stock is "Buy." The 12-month stock price target is ¥780, which is an increase of 215.72% from the latest price.

Price Target

¥780

(215.72% upside)

Analyst Consensus: Buy

Stock Forecasts